CytoDyn Inc. has presented promising early results from its ongoing Phase 2 study of leronlimab, a monoclonal antibody targeting the CCR5 receptor, in combination with TAS-102 and bevacizumab for patients with metastatic colorectal cancer (mCRC). The findings, showcased at the AACR Annual Meeting 2026, indicate that CCR5 inhibition may significantly modulate the tumor microenvironment, enhance immune engagement, and improve clinical outcomes in this challenging patient population.

The study highlights that 100% of evaluable samples exhibited CCR5 expression, underscoring its potential as a therapeutic target in mCRC. Notably, early clinical responses included a median decline of approximately 70% in circulating tumor DNA (ctDNA) by week two among evaluable patients. The combination therapy has demonstrated a favorable safety profile, with no dose-limiting toxicities reported, and the trial is progressing towards full enrollment, addressing the substantial unmet need in heavily pretreated mCRC patients.

The implications of these findings are significant for the field, as they reinforce the role of CCR5 as a key regulator of the tumor microenvironment across various solid tumors. This research not only supports the therapeutic potential of leronlimab in overcoming treatment resistance but also emphasizes the importance of integrating liquid biopsy biomarkers into clinical assessments. Such advancements could reshape the current paradigms in mCRC treatment strategies and expedite the development of combination therapies aimed at enhancing immune responses in resistant cancer types.

Source: globenewswire.com